Pfizer Inc. – beating out numerous other bidders – said it would buy U.S. cancer drug company Medivation Inc. for $14 billion in cash.
New timelines were announced for a U.S. FDA decision on Iglarlixi, the fixed-ratio combination of Adlyxin (lixisenatide) and Lantus, for treating type 2 diabetes.
Verily, Google’s life sciences division, needs more time to complete the construction of its new campus in the Bay Area.
Privately held DS Biopharma is spinning out a new company called Afimmune that is focused solely on fibrotic conditions such as NASH and pulmonary disorders including COPD and IPF.
Donald A. Henderson, who headed the World Health Organization vaccination effort that wiped out smallpox in 1977 and later became a U.S. bioterrorism expert, has died from complications following a hip fracture, officials said.
One of the top U.S. public health officials warned that the mosquito-borne Zika virus could extend its reach across the U.S. Gulf Coast after officials confirmed it as active in the popular tourist destination of Miami Beach.
China’s healthcare system is overly reliant on large over-burdened hospitals, which will struggle to cope with a spike in diseases linked to the fast-aging population, the World Health Organization said.
A Korean investment firm along with three South Korean securities firms has snapped up the North American headquarters of Novo Nordisk for $305 million.
Casebia Therapeutics, a joint venture between Bayer and CRISPR Therapeutics, plans to open laboratory and office space in Cambridge, Mass.
The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences’ heart valves to patients at intermediate risk of complications if they underwent open heart surgery.